预约演示
更新于：2025-05-29
Paricalcitol
帕立骨化醇
更新于：2025-05-29
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-04-17), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C27H44O3 |
InChIKeyBPKAHTKRCLCHEA-UBFJEZKGSA-N |
CAS号131918-61-1 |
关联
115
项与 帕立骨化醇 相关的临床试验NCT06209268
The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients -a Randomised Placebo Controlled Trial
NCT05664880
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis
ChiCTR2200065308
Effect of radiofrequency parathyroid ablation versus local injection of Paricalcitol in the treatment of hyperparathyroidism secondary in chronic kidney disease: a multicenter, randomized, controlled trial
100 项与 帕立骨化醇 相关的临床结果
登录后查看更多信息
100 项与 帕立骨化醇 相关的转化医学
登录后查看更多信息
100 项与 帕立骨化醇 相关的专利（医药）
登录后查看更多信息
992
项与 帕立骨化醇 相关的文献（医药）2025-12-01INFLAMMATION RESEARCH
Paricalcitol promotes the maturation of immune granulomas in an experimental model of superoxide dismutase A-induced inflammation
Article
作者: Ma, Kriventsov ; Et, Ablyakimov ; Kriventsov, Maxim A ; Av, Kubyshkin
BACKGROUND:
- Granulomatous inflammation is a hallmark of several chronic inflammatory diseases, characterized by the formation of immune granulomas. The vitamin D receptor (VDR) and its ligands, such as paricalcitol, have demonstrated immunomodulatory effects on various immune cell subpopulations, including macrophages, dendritic cells, and T-cells. However, the precise role of VDR activation in granuloma formation and the associated immune regulatory pathways, including the PD-1/PD-L1 axis, remains poorly understood. This study aimed to evaluate the effects of paricalcitol, a selective VDR agonist, on granuloma formation and immune cell composition in an experimental model of superoxide dismutase A (SoDA)-induced inflammation, with a focus on antigen-presenting cells (including CD68 + and CD1a + cells), T- and B-cell populations, and PD-L1 expression.
MATERIALS AND METHODS:
- The study involved 90 male Wistar rats divided into control and experimental groups. Experimental animals received paricalcitol intraperitoneally at different time points relative to sensitization with SoDA and complete Freund's adjuvant. Granulomatous infiltrates were evaluated histologically, and the cellular composition was assessed via immunohistochemistry using markers such as CD68, CD3, CD1a, CD20, and PD-L1. Statistical analysis included quantitative morphometry and group comparisons.
RESULTS:
- Paricalcitol administration significantly influenced granuloma development, with groups receiving treatment before (E1) or at the time of sensitization (E2) showing a reduction in immature granulomas and an increase in mature granulomas compared to the control groups. Enhanced macrophage differentiation, characterized by increased multinucleated giant cells and epithelioid cells, was observed. Additionally, there was a significant increase in PD-L1 expression in granulomatous infiltrates of treated groups, particularly in peripherally located immune cells. These effects were accompanied by a modulation of T-cell responses, including a reduction in CD3 + T-cell population.
CONCLUSION:
- The findings suggest that paricalcitol promotes granuloma stabilization and maturation by modulating VDR-mediated immune pathways, including maturation and transformation of macrophages into epithelioid and giant multinucleated cells, increase in number of CD1a + cells, and PD-1/PD-L1 axis regulation. The ability of paricalcitol to enhance PD-L1 expression through the VDR-mediated pathways provides additional evidence for its role in preventing excessive immune responses and highlights the therapeutic potential of VDR agonists in managing granulomatous inflammation.
2025-05-01TOXICOLOGY AND APPLIED PHARMACOLOGY
Paricalcitol, an active vitamin D analog, mitigates dexamethasone-induced hepatic injury: Role of autophagy, pyroptosis, and PERK/Nrf2/HO-1 signaling pathway
Article
作者: Elshal, Mahmoud ; El-Waseif, Aamal G ; El-Kashef, Dalia H ; Abu-Elsaad, Nashwa M
Drug-induced toxicity is considered a crucial clinical affair, as some adverse effects could be severe or life threatening. Drugs may have adverse effects by altering biological pathways that aren't always involved in the drug's reaction. From this perspective, the purpose of the current study was to assess the impacts of paricalcitol, a synthetic, active, and selective vitamin D receptor activator, on dexamethasone-induced liver injury, and discover the probable implicated signaling pathways as well. Male Wistar rats were treated with paricalcitol at a dose of 0.2 μg/kg, daily, i.p for 12 days and injected with 8 mg/kg dexamethasone i.p daily over the last 6 days. Administration of paricalcitol improved liver function markers, lipid profile, reduced histopathologic changes in hepatic sections, and restored normal oxidative status. Moreover, paricalcitol markedly decreased hepatic collagen deposition as confirmed by Masson's trichrome staining. Paricalcitol effectively inhibited endoplasmic reticulum stress through decreasing expression of tissue PERK and Chop, increasing hepatic Nrf2, and HO-1 activity. Besides, paricalcitol decreased levels of NLRP3 and IL-1β as well as decreased expression of active caspase-1 p20, GSDMD-N-terminal indicating suppression of NLRP3/caspase-1/GSDMD pyroptosis pathway. Paricalcitol can protect against dexamethasone-induced liver injury showing a promising therapeutic value in drug-induced liver injuries.
2025-03-01Health Science Reports
Effects of Vitamin D Supplementation on Blood Pressure in Patients With Type 1 Diabetes Mellitus: A Systematic Review of Clinical Trials
Review
作者: Mohammad Soltani, Sana ; Masouri, Mohammad Mahdi ; Nejadghaderi, Seyed Aria ; Ebrahimi, Rasoul ; Salehi Amniyeh Khozani, Amir Abbas
ABSTRACT:
Background and Aims:
Hypertension exacerbates cardiovascular risks in patients with type 1 diabetes mellitus (T1DM), necessitating effective blood pressure (BP) management. Vitamin D deficiency is common in T1DM patients and is associated with an increased risk of cardiovascular diseases. This systematic review aimed to evaluate the impact of vitamin D supplementation on BP in T1DM patients.
Methods:
PubMed, Web of Science, Embase, Scopus, and Google Scholar were searched until March 2024. Clinical trials reported BP outcomes in patients with T1DM after vitamin D supplementation were included. Other types of studies and studies that did not report BP outcomes and those that had populations other than patients with T1DM were excluded. The National Institutes of Health (NIH) tool was used for the risk of bias assessment.
Results:
In total, eight studies, involving 328 participants, were included in this review. They were conducted between 2014 and 2024, with mostly conducted in Brazil (n = 5). While one study demonstrated a significant reduction in morning systolic and diastolic BP after vitamin D supplementation, five studies found no significant differences in systolic or diastolic BP. Another study noted a significant reduction in morning systolic and diastolic BP, with no significant changes in 24‐h ambulatory monitoring. Also, paricalcitol therapy did not significantly reduce systolic and diastolic ambulatory BP compared to placebo.
Conclusion:
The current evidence on the effect of vitamin D supplementation on blood pressure in patients with T1DM remains inconclusive. Nonetheless, more randomized controlled studies with larger sample sizes and longer follow‐up durations are essential to establish the association between vitamin D and BP in this population.
100 项与 帕立骨化醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 继发性甲状旁腺功能亢进症 | 美国 | 1998-04-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白蛋白尿 | 临床3期 | 斯洛文尼亚 | 2012-07-01 | |
| 肾脏疾病 | 临床3期 | 斯洛文尼亚 | 2012-07-01 | |
| 糖尿病肾病 | 临床3期 | 瑞典 | 2010-09-01 | |
| 冠心病 | 临床3期 | 美国 | 2010-01-01 | |
| 维生素D缺乏症 | 临床3期 | 美国 | 2010-01-01 | |
| 左心室肥大 | 临床3期 | 美国 | 2008-02-01 | |
| 左心室肥大 | 临床3期 | 澳大利亚 | 2008-02-01 | |
| 左心室肥大 | 临床3期 | 捷克 | 2008-02-01 | |
| 左心室肥大 | 临床3期 | 德国 | 2008-02-01 | |
| 左心室肥大 | 临床3期 | 意大利 | 2008-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 16 | 鏇選願膚願鑰鹽鹽餘選(製網遞衊膚顧鹽築願壓) = 網選憲獵觸網築獵鑰憲 夢選觸壓鏇願餘鑰壓壓 (鬱範簾製衊窪願繭艱鑰 ) 更多 | 不佳 | 2024-04-05 | |||
ISN WCN2024 人工标引  | N/A | 慢性肾病 FGF23 | 20 | 糧廠艱醖鏇遞窪壓憲觸(選憲壓艱選廠糧鹽範網) = Initial diastolic function Z-scores (n=11) were significantly different from mean normal controls (all p<0.05) suggesting DD. Follow-up Z-scores of diastolic function during Pc treatment (15.6 ± 12.4 μg/week) were similar to baseline. 選製鏇膚餘築鬱顧製蓋 (淵鑰願鹽齋憲鹹範鏇襯 ) 更多 | 积极 | 2024-04-01 | |
早期临床1期 | 3 | 網鏇繭鬱壓餘顧鹹範願(衊獵夢範製鹽蓋襯遞窪) = 鬱鹹齋繭鏇衊糧窪齋夢 窪糧夢積糧鑰積鏇膚願 (糧鹹觸鑰願糧壓繭餘觸, 4.2) 更多 | - | 2024-03-15 | |||
(Arm B) | 網鏇繭鬱壓餘顧鹹範願(衊獵夢範製鹽蓋襯遞窪) = 窪顧顧壓夢衊築餘繭鹹 窪糧夢積糧鑰積鏇膚願 (糧鹹觸鑰願糧壓繭餘觸, 0) 更多 | ||||||
临床2期 | 24 | (Pembrolizumab & Paricalcitol) | 蓋築廠簾範壓膚繭選範 = 構鏇築膚衊醖糧醖鹹繭 觸憲範蓋範築窪觸壓艱 (鬱夢壓構範膚製簾製鏇, 製鬱積範壓鬱淵糧觸構 ~ 醖蓋醖襯襯艱窪淵鬱觸) 更多 | - | 2022-12-27 | ||
placebo+pembrolizumab (Pembrolizumab & Placebo) | 蓋築廠簾範壓膚繭選範 = 醖範簾壓鏇簾醖蓋壓積 觸憲範蓋範築窪觸壓艱 (鬱夢壓構範膚製簾製鏇, 築窪鑰鑰衊觸鹽鹽淵鹹 ~ 餘淵顧築艱觸艱齋鹽構) 更多 | ||||||
N/A | - | 蓋糧願範艱廠衊膚鬱簾(鬱糧網憲遞積醖襯鹹範) = 6-12 months, 12-24 months and overall differences were statistically significant 憲餘壓夢築選遞製鹹鹽 (醖觸艱窪鹹範積蓋獵簾 ) 更多 | - | 2022-11-06 | |||
N/A | - | 築範築廠鏇網襯壓齋蓋(鏇繭廠蓋憲選鏇艱淵獵) = 網繭遞範夢簾淵繭製醖 築憲遞鬱構鑰鹽艱襯獵 (餘繭簾獵廠製憲淵遞憲 ) | 积极 | 2022-11-04 | |||
N/A | 肾性贫血 secondary hyperparathyroidism | plasma creatinine | iPTH | 52 | 選夢廠餘膚醖繭簾選獵(獵製範淵襯顧醖鏇網鹽) = 鑰醖衊簾餘鑰簾鬱鹹鏇 壓艱廠夢遞襯壓鹽繭憲 (齋憲簾餘顧構襯淵糧鑰, 0.4 ~ 1.2) | 积极 | 2022-05-03 | ||
Erythropoietin stimulating agents (ESA) | 選夢廠餘膚醖繭簾選獵(獵製範淵襯顧醖鏇網鹽) = 製鑰繭積膚壓膚觸夢鹽 壓艱廠夢遞襯壓鹽繭憲 (齋憲簾餘顧構襯淵糧鑰, 0.4 ~ 1.2) | ||||||
N/A | - | 餘築鬱積襯製艱蓋鬱鹹(築構遞顧繭製襯襯製窪) = 壓獵廠襯遞構衊衊鹽製 蓋鹽鹹憲選獵艱積鏇簾 (選廠鹽構鹽顧醖鹹遞壓 ) | 积极 | 2022-05-03 | |||
餘築鬱積襯製艱蓋鬱鹹(築構遞顧繭製襯襯製窪) = 鑰選廠淵鹹鹽齋願鏇壓 蓋鹽鹹憲選獵艱積鏇簾 (選廠鹽構鹽顧醖鹹遞壓 ) | |||||||
临床1期 | 20 | (dose level 1) | 築壓鬱餘構糧餘廠簾獵(鹹積積艱顧壓選鑰窪夢) = 鬱願選壓簾築鹹夢構廠 醖衊襯築構醖餘鬱選窪 (鏇顧鏇觸積鹹餘築壓範 ) 更多 | 不佳 | 2022-01-19 | ||
(dose level 2) | 築壓鬱餘構糧餘廠簾獵(鹹積積艱顧壓選鑰窪夢) = 繭願築鏇夢網膚鹹襯鹹 醖衊襯築構醖餘鬱選窪 (鏇顧鏇觸積鹹餘築壓範 ) 更多 | ||||||
临床2期 | 32 | 鏇蓋廠繭築顧艱醖鬱糧(願鏇簾繭膚膚膚繭繭築) = 蓋簾觸鹹膚繭夢網構夢 醖鹹壓鹽簾齋鹽齋遞廠 (簾願顧壓獵積蓋淵顧夢, 5 ~ 8) 更多 | 积极 | 2021-11-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用